Development of Novel Technology of DDS for Gene Therapy

Drug Metabolism and Pharmacokinetics

Volumn 18, Issue 4, 2003, Pages 223-229

  Nakagawa, Shinsaku ^a   Mayumi, Tadanori ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

cytoplasmic gene expression system; DDS; fusogenic liposome; gene expression system; gene therapy; tetracyclineregulatable

Indexed keywords

EID: 25144451484     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.223     Document Type: Review

References (35)

1. Lechardeur, D. et al.: Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther., 6: 482-497 (1999).
2. Fisher, T. L., Terhorst, T., Cao, X. and Wagner, R. W.: Intracellular disposition and metabolism of fluorescen-tly-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res., 21: 3857-3865 (1993).
3. Crooke, R. M. et al.: Metabolism of antisense oligonucleotides in rat liver homogenates. J. Pharmacol. Exp. Ther., 292: 140-149 (2000).
4. Caruso, M., Pham Nguyen K., Kwong, Y. L., Xu, B., Kosai, K. I., Finegold, M., Woo, S. L. and Chen, S. H.,: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA, 93: 11302-11306 (1996).
5. Bramson, J. L., Hitt, M., Addison, C. L., Muller, W. J., Gauldie, J. and Graham, F. L.: Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther., 7: 1995-2002 (1996).
6. Bui, L. A., Butterfield, L. H., Kim, J. Y., Ribas, A., Seu, P., Lau, R., Glaspy, J. A., McBride, W. H. and Economou, J. S.: In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum. Gene Ther., 8: 2173-2182 (1997).
7. Putzer, B. M., Bramson, J. L., Addison, C. L., Hitt, M., Siegel, P. M., Muller, W. J. and Graham, F. L.: Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum. Gene Ther., 9: 707-718 (1998).
8. Tjuvajev, J., Gansbacher, B., Desai, R., Beattie, B., Kaplitt, M., Matei, C., Koutcher, J., Gilboa, E. and Blasberg, R.: RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res., 55: 1902-1910 (1995).
9. Putzer, B. M., Hitt, M., Muller, W. J., Emtage, P., Gauldie, J. and Graham, F. L.: Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA, 94: 10889-10994 (1997).
10. Mizuguchi, H., et al.: Efficient gene transfer into mammalian cells using fusogenic liposome. Biochem. Biophs. Res. Commun., 218: 402-407 (1996).
11. Mizuguchi, H., et al.: A novel gene transfer system using fusogenic liposomes. Progress in Drug Delivery System, V: 149-152 (1996).
12. Mizuguchi, H., et al.: Development of fusogenic liposomes and its application to gene therapy. Transaction of the Materials Research Society of Japan, (MRS-J) 20, 21-24, (1996).
13. Hayashi, A., et al.: A novel vaccine delivery system using immunopotentiating fusogenic liposomes. Biochem. Biophys. Res. Commun., 261: 824-828 (1999).
14. Nakanishi, T., et al.: Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur. J. Immunol., 30: 1740-1747 (2000).
15. Mizuguchi, H., et al.: Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy. Br. J. Cancer, 73: 472-476 (1996).
16. Mizuguchi, H., et al.: Intratumor administration of fusogenic liposomes containing fragment A of diphtheria toxin suppresses tumor growth. Cancer Lett., 100: 63-69 (1996).
17. Kondoh, M., et al.: Growth inhibition of human leukemia HL-60 cells by an antisense phosphodiester oligonucleotide encapsulated into fusogenic liposomes. Biol. Pharm. Bull., 23: 1011-1013 (2000).
18. Greber, U. F., et al.: Stepwise dismantling of adenovirus 2 during entry into cells. Cell, 75: 477-486 (1993).
19. Mizuguchi, H., et al.: Cytoplasmic gene expression system enhances the efficiency of cationic liposome-mediated in vivo gene transfer into mouse brain. Biochem. Biophys. Res. Commun., 234: 15-18 (1997).
20. Nakano, R., et al.: A nobel T7 system utilizing mRNA coding for T7 RNA polymerase. Biochem. Biophys. Res. Commun., 301: 974-978 (2003).
21. Nouer, L.: in Heat Shock Response, ed. Nouer, L. (CRC, Boca Raton, FL), pp. 167-220 (1991).
22. Lee, F., Mulligan, R., Berg, P. and Ringold, G.: Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumour virus chimaeric plasmids. Nature, 294: 228-232 (1981).
23. Hynes, N. E., Kennedy, N., Rahmsdorf, U. and Groner, B.: Hormone-responsive expression of an endogenous proviral gene of mouse mammary tumor virus after molecular cloning and gene transfer into cultured cells. Proc. Natl. Acad. Sci. USA, 78: 2038-2042 (1981).
24. Klock, G., Strahle, U. and Schutz, G.: Oestrogen and glucocorticoid responsive elements are closely related but distinct. Nature, 329: 734-736 (1987).
25. Israel-D. I., Kaufman-R. J.: Highly inducible expression from vectors containing multiple GRE's in CHO cells overexpressing the glucocorticoid receptor. Nucleic-Acids-Res., 17: 4589-4604 (1989).
26. Mayo, K. E., Warren, R. and Palmiter, R. D.: The mouse metallothionein-I gene is transcriptionally regulated by cadmium following transfection into human or mouse cells. Cell, 29: 99-108 (1982).
27. Brinster, R. L., Chen, H. Y., Warren, R., Sarthy, A. and Palmiter, R. D.: Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs. Nature, 296: 39-42 (1982).
28. Searle, P. F., Stuart, G. W. and Palmiter, R. D.: Building a metal-responsive promoter with synthetic regulatory elements. Mol. Cell. Biol., 5: 1480-1489 (1985).
29. Anton, M. and Graham, F. L.: Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J. Virol., 69: 4600-4606 (1995).
30. Kanegae, Y., Lee, G., Sato, Y., Tanaka, M., Nakai, M., Sakaki, T., Sugano, S. and Saito, I.: Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic. Acids. Res., 23, 3816-3821 (1995).
31. Fukushige, S. and Sauer, B.: Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA, 89: 7905-7909 (1992).
32. Gossen, M. and Bujard, H.: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA, 89, 5547-5551 (1992).
33. Hillen, W. and Wissmann, A.: in Protein-Nucleic Acid Interaction, Topics in Molecular and Structural Biology, eds. Saenger, W. and Heinemann, U., Macmillan, London, Vol. 10, pp. 143-162 (1989).
34. Gossen, M., et al.: Transcriptional activation by tetracyclines in mammalian cells. Science, 268: 1766-1769 (1995).
35. Nakagawa, S., et al.: Tetracycline-regulatable adenovirus vectors: pharmacologic properties and clinical potential. European J. Pharmaceutical Sciences, 13: 53-60 (2002).